An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma

Anna Maria Storniolo, Nathan H. Enas, Cheryl A. Brown, Maurizio Voi, Mace L. Rothenberg, Richard Schilsky

Research output: Contribution to journalArticle

247 Citations (Scopus)

Abstract

BACKGROUND. An Investigational New Drug (IND) treatment program allows patients access to a drug that has shown activity against a serious or life- threatening disease prior to full Food and Drug Administration (FDA) review and approval. This treatment IND program, in which patients with locally advanced or metastatic pancreatic carcinoma were treated with gemcitabine, began in 1995. METHODS. Eligibility criteria were ≤1 prior chemotherapy regimen; a Kamofsky performance status (KPS) of ≥50; and adequate bone marrow, liver, and renal function. Gemcitabine was given at a dose of 1000 mg/m2 weekly x 7 followed by a week of rest, then weekly x 3 every 4 weeks thereafter. In this program, diseaserelated symptom improvement (DRSI) was defined retrospectively as 1) improvement in pain (on a 7-point scale) and/or analgesic class (e.g., morphine improving to codeine) and/or KPS (≥20 points), or 2) stability of these three parameters with a 7% increase in weight from baseline. RESULTS. A total of 3023 patients enrolled. At baseline, 80% of them had Stage IV disease, and 84% had a baseline KPS ≥ 70. The median age was 65 years, and 56% of the patients were male. The cumulative DRSI response rate after the fourth cycle was 18.4%. Of 982 patients with tumor response data, there were 14 with complete response and 104 with partial response, for an overall response rate of 12.0% (95% confidence interval [CI], 10.0-14.0%). For 2380 patients with survival data, the median survival was 4.8 months (95% CI, 4.5-5.1 months) and the 12-month survival was 15%. Gemcitabine was well tolerated; only 4.6% of discontinuations were due to adverse events. CONCLUSIONS. Notable disease- related symptom improvement and survival were seen with gemcitabine in this large, compassionate-use setting, and these findings were in agreement with those of earlier registration thais.

Original languageEnglish (US)
Pages (from-to)1261-1268
Number of pages8
JournalCancer
Volume85
Issue number6
DOIs
StatePublished - Mar 15 1999

Fingerprint

gemcitabine
Investigational Drugs
Survival
Therapeutics
Compassionate Use Trials
Confidence Intervals
Codeine
United States Food and Drug Administration
Morphine
Analgesics
Pancreatic Carcinoma
Bone Marrow
Kidney
Weights and Measures
Drug Therapy
Pain

Keywords

  • Clinical benefit
  • Diseaserelated symptom improvement
  • Gemcitabine
  • Pain
  • Pancreatic carcinoma
  • Performance status
  • Quality of life
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

An investigational new drug treatment program for patients with gemcitabine : Results for over 3000 patients with pancreatic carcinoma. / Storniolo, Anna Maria; Enas, Nathan H.; Brown, Cheryl A.; Voi, Maurizio; Rothenberg, Mace L.; Schilsky, Richard.

In: Cancer, Vol. 85, No. 6, 15.03.1999, p. 1261-1268.

Research output: Contribution to journalArticle

Storniolo, Anna Maria ; Enas, Nathan H. ; Brown, Cheryl A. ; Voi, Maurizio ; Rothenberg, Mace L. ; Schilsky, Richard. / An investigational new drug treatment program for patients with gemcitabine : Results for over 3000 patients with pancreatic carcinoma. In: Cancer. 1999 ; Vol. 85, No. 6. pp. 1261-1268.
@article{9ce556903890401bb56c3b98d35db0d4,
title = "An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma",
abstract = "BACKGROUND. An Investigational New Drug (IND) treatment program allows patients access to a drug that has shown activity against a serious or life- threatening disease prior to full Food and Drug Administration (FDA) review and approval. This treatment IND program, in which patients with locally advanced or metastatic pancreatic carcinoma were treated with gemcitabine, began in 1995. METHODS. Eligibility criteria were ≤1 prior chemotherapy regimen; a Kamofsky performance status (KPS) of ≥50; and adequate bone marrow, liver, and renal function. Gemcitabine was given at a dose of 1000 mg/m2 weekly x 7 followed by a week of rest, then weekly x 3 every 4 weeks thereafter. In this program, diseaserelated symptom improvement (DRSI) was defined retrospectively as 1) improvement in pain (on a 7-point scale) and/or analgesic class (e.g., morphine improving to codeine) and/or KPS (≥20 points), or 2) stability of these three parameters with a 7{\%} increase in weight from baseline. RESULTS. A total of 3023 patients enrolled. At baseline, 80{\%} of them had Stage IV disease, and 84{\%} had a baseline KPS ≥ 70. The median age was 65 years, and 56{\%} of the patients were male. The cumulative DRSI response rate after the fourth cycle was 18.4{\%}. Of 982 patients with tumor response data, there were 14 with complete response and 104 with partial response, for an overall response rate of 12.0{\%} (95{\%} confidence interval [CI], 10.0-14.0{\%}). For 2380 patients with survival data, the median survival was 4.8 months (95{\%} CI, 4.5-5.1 months) and the 12-month survival was 15{\%}. Gemcitabine was well tolerated; only 4.6{\%} of discontinuations were due to adverse events. CONCLUSIONS. Notable disease- related symptom improvement and survival were seen with gemcitabine in this large, compassionate-use setting, and these findings were in agreement with those of earlier registration thais.",
keywords = "Clinical benefit, Diseaserelated symptom improvement, Gemcitabine, Pain, Pancreatic carcinoma, Performance status, Quality of life, Survival",
author = "Storniolo, {Anna Maria} and Enas, {Nathan H.} and Brown, {Cheryl A.} and Maurizio Voi and Rothenberg, {Mace L.} and Richard Schilsky",
year = "1999",
month = "3",
day = "15",
doi = "10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T",
language = "English (US)",
volume = "85",
pages = "1261--1268",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - An investigational new drug treatment program for patients with gemcitabine

T2 - Results for over 3000 patients with pancreatic carcinoma

AU - Storniolo, Anna Maria

AU - Enas, Nathan H.

AU - Brown, Cheryl A.

AU - Voi, Maurizio

AU - Rothenberg, Mace L.

AU - Schilsky, Richard

PY - 1999/3/15

Y1 - 1999/3/15

N2 - BACKGROUND. An Investigational New Drug (IND) treatment program allows patients access to a drug that has shown activity against a serious or life- threatening disease prior to full Food and Drug Administration (FDA) review and approval. This treatment IND program, in which patients with locally advanced or metastatic pancreatic carcinoma were treated with gemcitabine, began in 1995. METHODS. Eligibility criteria were ≤1 prior chemotherapy regimen; a Kamofsky performance status (KPS) of ≥50; and adequate bone marrow, liver, and renal function. Gemcitabine was given at a dose of 1000 mg/m2 weekly x 7 followed by a week of rest, then weekly x 3 every 4 weeks thereafter. In this program, diseaserelated symptom improvement (DRSI) was defined retrospectively as 1) improvement in pain (on a 7-point scale) and/or analgesic class (e.g., morphine improving to codeine) and/or KPS (≥20 points), or 2) stability of these three parameters with a 7% increase in weight from baseline. RESULTS. A total of 3023 patients enrolled. At baseline, 80% of them had Stage IV disease, and 84% had a baseline KPS ≥ 70. The median age was 65 years, and 56% of the patients were male. The cumulative DRSI response rate after the fourth cycle was 18.4%. Of 982 patients with tumor response data, there were 14 with complete response and 104 with partial response, for an overall response rate of 12.0% (95% confidence interval [CI], 10.0-14.0%). For 2380 patients with survival data, the median survival was 4.8 months (95% CI, 4.5-5.1 months) and the 12-month survival was 15%. Gemcitabine was well tolerated; only 4.6% of discontinuations were due to adverse events. CONCLUSIONS. Notable disease- related symptom improvement and survival were seen with gemcitabine in this large, compassionate-use setting, and these findings were in agreement with those of earlier registration thais.

AB - BACKGROUND. An Investigational New Drug (IND) treatment program allows patients access to a drug that has shown activity against a serious or life- threatening disease prior to full Food and Drug Administration (FDA) review and approval. This treatment IND program, in which patients with locally advanced or metastatic pancreatic carcinoma were treated with gemcitabine, began in 1995. METHODS. Eligibility criteria were ≤1 prior chemotherapy regimen; a Kamofsky performance status (KPS) of ≥50; and adequate bone marrow, liver, and renal function. Gemcitabine was given at a dose of 1000 mg/m2 weekly x 7 followed by a week of rest, then weekly x 3 every 4 weeks thereafter. In this program, diseaserelated symptom improvement (DRSI) was defined retrospectively as 1) improvement in pain (on a 7-point scale) and/or analgesic class (e.g., morphine improving to codeine) and/or KPS (≥20 points), or 2) stability of these three parameters with a 7% increase in weight from baseline. RESULTS. A total of 3023 patients enrolled. At baseline, 80% of them had Stage IV disease, and 84% had a baseline KPS ≥ 70. The median age was 65 years, and 56% of the patients were male. The cumulative DRSI response rate after the fourth cycle was 18.4%. Of 982 patients with tumor response data, there were 14 with complete response and 104 with partial response, for an overall response rate of 12.0% (95% confidence interval [CI], 10.0-14.0%). For 2380 patients with survival data, the median survival was 4.8 months (95% CI, 4.5-5.1 months) and the 12-month survival was 15%. Gemcitabine was well tolerated; only 4.6% of discontinuations were due to adverse events. CONCLUSIONS. Notable disease- related symptom improvement and survival were seen with gemcitabine in this large, compassionate-use setting, and these findings were in agreement with those of earlier registration thais.

KW - Clinical benefit

KW - Diseaserelated symptom improvement

KW - Gemcitabine

KW - Pain

KW - Pancreatic carcinoma

KW - Performance status

KW - Quality of life

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0033559213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033559213&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T

DO - 10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T

M3 - Article

C2 - 10189130

AN - SCOPUS:0033559213

VL - 85

SP - 1261

EP - 1268

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -